Mid-regional pro-atrial natriuretic peptide and the assessment of volaemic status and differential diagnosis of profound hyponatraemia

What Was Tested

This observational study looks at ANP (Atrial Natriuretic Peptide).

Hyponatraemia is common and its differential diagnosis and consequent therapy management is challenging.

The differential diagnosis is mainly based on the routine clinical assessment of volume status, which is often misleading.

Who Took Part

The study group was 227 patients.

PubMed indexes the participants as middle-aged adults, older adults and people over 80, both men and women.

A standardized diagnostic evaluation of the underlying cause of hyponatraemia was performed, and an expert panel carefully evaluated volaemic status using clinical criteria.

MR-proANP levels were compared between patients with hyponatraemia of different aetiologies and for assessment of volume status.

How the Study Was Run

The design is described as multicenter.

Running at several centres spread the ANP (Atrial Natriuretic Peptide) study over different clinics and patient groups.

What Was Measured

The differential diagnosis is mainly based on the routine clinical assessment of volume status, which is often misleading.

The subject headings attached to it are Atrial Natriuretic Factor, Biomarkers, Blood Volume, Diagnosis, Differential, Extracellular Fluid, Heart Failure and Hyponatremia.

The authors tagged it with the keywords mid-regional pro-atrial natriuretic peptide, profound hyponatraemia and volume status.

What This Means in Plain Language

The paper is a multicenter study of ANP (Atrial Natriuretic Peptide) in 227 patients.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (Journal of internal medicine), a journal based in England.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.